Protozoal infections:

Indications for: LAMPIT

Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi in pediatric patients (birth to <18yrs of age and weighing ≥2.5kg).

Adult Dosage:

Not applicable.

Children Dosage:

Swallow whole or divide in half by hand; do not use a tablet splitting device. If unable to swallow, tabs may be dispersed in water and administered as a slurry. Give 3 times daily with food for 60 days. Total daily dose: <18yrs (<41kg): 10–20mg/kg; (≥41kg): 8–10mg/kg. Individual dose: <18yrs (<2.5kg): not established; (2.5–4.5kg): 15mg; (4.6–<9kg): 30mg; (9–<13kg): 45mg; (13–<18kg): 60mg; (18–<22kg): 75mg; (22–<27kg): 90mg; (27–<35kg): 120mg; (35–<41kg): 180mg; (41–<51kg): 120mg; (51–<71kg): 180mg; (71–<91kg): 240mg; (≥91kg): 300mg.

LAMPIT Contraindications:

Consuming alcohol during treatment.

LAMPIT Warnings/Precautions:

Discontinue at the 1st sign of serious hypersensitivity. History of brain injury, seizures, psychiatric disease, serious behavioral alterations, neurological disturbances, psychiatric drug reactions, porphyria: administer under close medical supervision. Monitor body weight every 14 days; dose adjustment may be needed. Renal or hepatic impairment. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners to use condoms) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: monitor infants.

LAMPIT Classification:


LAMPIT Interactions:

See Contraindications. Potentiated by alcohol.

Adverse Reactions:

Vomiting, abdominal pain, headache, decreased appetite, nausea, pyrexia, rash; worsening of neurological and psychiatric conditions, hypersensitivity, weight loss, porphyria; potential for genotoxicity and carcinogenicity.


Primary mediated via nitroreductases.

Drug Elimination:

Renal (~44% and 27% under fed and fasted conditions, respectively). Half-life: 2.4–3.6 hours.

Generic Drug Availability:


How Supplied: